Navigation Links
BioSpecifics Technologies Corp. Stock Trading Halted Today
Date:9/16/2009

LYNBROOK, N.Y., Sept. 16 /PRNewswire-FirstCall/ -- BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, today announced that NASDAQ has halted trading of the Company's common stock this morning. The Arthritis Advisory Committee appointed by the U.S. Food and Drug Administration's (FDA) Division of Anesthesia, Analgesia and Rheumatology Products will be meeting today to review and discuss the Biologics License Application (BLA) for XIAFLEX(TM) for the treatment of Dupuytren's disease, a debilitating disorder resulting from excessive collagen deposition that causes contractures of the fingers. Auxilium Pharmaceuticals, Inc. has licensed the rights to XIAFLEX from BioSpecifics for this indication.

About BioSpecifics Technologies Corp.

BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for three clinical indications: Dupuytren's disease; Peyronie's disease; and frozen shoulder (adhesive capsulitis). Its strategic partner Auxilium Pharmaceuticals, Inc. has announced the acceptance of the Biologic License Application (BLA) and Priority Review by the U.S. Food and Drug Administration for injectable collagenase XIAFLEX(TM) in the treatment of Dupuytren's disease. Pfizer, Inc. is responsible for marketing XIAFLEX(TM) product in Europe.


'/>"/>
SOURCE BioSpecifics Technologies Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BioSpecifics Technologies Corp. To Present at BioCentury NewsMakers in the Biotech Industry Conference
2. BioSpecifics Technologies Corp. to Present at Rodman & Renshaw 11th Annual Healthcare Conference
3. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
4. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2009 Financial Results on August 12, 2009
5. BioSpecifics Technologies Corp. to Present at CapStone Investments Third Annual Small-Cap Investor Conference
6. BioSpecifics Technologies Corp. Added to Russell 3000 and Russell 2000 Indexes
7. BioSpecifics Technologies Corp. Reports First Quarter 2009 Financial Results
8. BioSpecifics Technologies Corp. Announces FDA Acceptance of Biologics License Application With Priority Review for XIAFLEX(TM) for the Treatment of Dupuytrens Disease
9. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
10. BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market
11. BioSpecifics Technologies Corp. to Present at Piper Jaffray 20th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... MA (PRWEB) , ... February 24, 2017 , ... ... replacement (TDR) procedures can be safely completed in an ambulatory surgery center (ASC) ... fusion (ACDF) procedures and previous two-year TDR studies. , Jake Lubinski, president ...
(Date:2/24/2017)... 24, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: ... a clinical-stage oncology and dermatology biopharmaceutical company, today ... participate in its previously announced rights offering of ... of common stock and Series C Convertible Preferred ... warrants. As previously announced, the ...
(Date:2/24/2017)... , Feb. 24, 2017  Driven by consumers, ... are now the fastest growing categories, finds the ... Actives in Personal Care: Multi-regional Market Analysis and ... management consulting firm Kline. "Biotechnology actives ... make them more effective for skin and hair ...
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" ... in China, today announced its financial results for the fourth ... Quarter 2016 Financial Highlights Total sales ... RMB terms, or increased by 13.6% in USD terms to ... 2015. Gross profit increased by 13.3% to ...
Breaking Biology Technology:
(Date:2/8/2017)... 7, 2017 The biometrics market has ... confluence of organizations, desires to better authenticate or ... (password and challenge questions), biometrics is quickly working ... The market is driven by use cases, though ... and enterprise uses cases, with consumer-facing use cases ...
(Date:2/7/2017)... , February 7, 2017 ... Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the "Company") ... electronic transaction processing services, is pleased to announce the ... Company. Effective January 31, 2017, Philip ... of Directors, CEO and President.  An experienced payment industry ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
Breaking Biology News(10 mins):